Market Summary
USD6.80+0.30
Market Closed4.62%
CRBP Stock Price
CRBP RSI Chart
CRBP Valuation
CRBP Price/Sales (Trailing)
CRBP Profitability
CRBP Fundamentals
CRBP Revenue
CRBP Earnings
Price Action
52 Week Range
0.1013.17
(Low)(High)
Last 7 days
-3.1%
Last 30 days
1.7%
Last 90 days
-22.6%
Trailing 12 Months
3677.8%
CRBP Financial Health
CRBP Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for CRBP
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2022-08-10 | Cohen Yuval | bought | 1,003 | 0.264 | 3,800 | chief executive officer |
2022-08-10 | Millian Craig Stuart | bought | 1,272 | 0.2545 | 5,000 | chief operating officer |
2022-08-10 | Moran Sean F. | bought | 5,198 | 0.2599 | 20,000 | chief financial officer |
2022-05-16 | Cohen Yuval | bought | 2,625 | 0.25 | 10,500 | chief executive officer |
2022-05-16 | Moran Sean F. | bought | 3,600 | 0.3 | 12,000 | chief financial officer |
2022-03-10 | Millian Craig Stuart | bought | 3,700 | 0.37 | 10,000 | chief operating officer |
2022-03-10 | Moran Sean F. | bought | 5,550 | 0.37 | 15,000 | chief financial officer |
2022-03-09 | Cohen Yuval | bought | 3,182 | 0.37 | 8,600 | chief executive officer |
2020-12-21 | Moran Sean F. | acquired | 122,500 | 1.4 | 87,500 | chief financial officer |
2020-12-21 | Moran Sean F. | sold | -153,125 | 1.75 | -87,500 | chief financial officer |
Which funds bought or sold CRBP recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -30.65 | -616 | 1,826 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 1.27 | 52.00 | 627 | -% |
2023-08-15 | Belpointe Asset Management LLC | sold off | -100 | -160 | - | -% |
2023-08-14 | VANGUARD GROUP INC | added | - | 102,293 | 1,406,940 | -% |
2023-08-14 | Royal Bank of Canada | new | - | 12,000 | 12,000 | -% |
2023-08-14 | Sio Capital Management, LLC | unchanged | - | 85,500 | 1,176,000 | 0.30% |
2023-08-14 | Tower Research Capital LLC (TRC) | reduced | -72.52 | -2,848 | 1,152 | -% |
2023-08-14 | BOOTHBAY FUND MANAGEMENT, LLC | unchanged | - | 21,646 | 297,732 | 0.01% |
2023-08-14 | NewEdge Advisors, LLC | unchanged | - | 5.00 | 63.00 | -% |
2023-08-14 | IFP Advisors, Inc | added | 100 | 24.00 | 34.00 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Corbus Pharmaceuticals Holdings
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Aug 24, 2022 | etf managers group, llc | 4.95% | 6,194,679 | SC 13G/A | |
| Feb 14, 2022 | etf managers group, llc | 8.78% | 10,995,143 | SC 13G/A | |
| Jun 01, 2021 | etf managers group, llc | 11.39% | 14,240,357 | SC 13G/A | |
| May 11, 2021 | etf managers group, llc | 5.34% | 6,673,458 | SC 13G/A | |
| Apr 12, 2021 | blackrock inc. | 4.5% | 5,673,664 | SC 13G/A | |
| Mar 17, 2021 | etf managers group, llc | 4.80% | 5,997,343 | SC 13G/A | |
| Feb 16, 2021 | etf managers group, llc | 6.96% | 5,851,347 | SC 13G/A | |
| Feb 12, 2021 | etf managers group, llc | 9.28% | 7,796,166 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 6.2% | 5,220,525 | SC 13G/A | |
| Jan 11, 2021 | state street corp | 1.59% | 1,333,546 | SC 13G/A |
Recent SEC filings of Corbus Pharmaceuticals Holdings
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 08, 2023 | 8-K | Current Report | |
| Aug 08, 2023 | 10-Q | Quarterly Report | |
| Aug 03, 2023 | 8-K | Current Report |
Peers (Alternatives to Corbus Pharmaceuticals Holdings)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 269.9B | 56.0B | 3.85% | 7.89% | 31.08 | 4.82 | -2.31% | -31.27% |
BGNE | 262.3B | 1.8B | -6.03% | 32.32% | -151.4 | 144.85 | 69.45% | 14.65% |
VRTX | 90.1B | 9.5B | -0.31% | 22.07% | 26.78 | 9.48 | 13.83% | 5.33% |
REGN | 88.3B | 12.7B | -1.90% | 19.84% | 20.53 | 6.97 | -10.94% | -24.40% |
ALNY | 21.4B | 1.2B | -9.89% | -15.37% | -20.15 | 17.32 | 39.94% | -8.44% |
SRPT | 11.2B | 1.0B | 4.78% | 8.17% | -12.32 | 11.15 | 20.15% | -79.16% |
UTHR | 10.4B | 2.1B | -3.76% | 7.10% | 11.99 | 4.95 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.0B | 225.6M | -0.48% | -26.20% | -5.42 | 13.31 | -2.11% | 21.02% |
MDGL | 2.8B | - | -14.43% | 145.38% | -8.58 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -0.46% | -15.55% | -3.61 | 6.46 | 20.50% | -42.46% |
MRTX | 2.4B | 27.2M | 9.19% | -41.38% | -3.24 | 87.87 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -6.35% | -39.96% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -14.43% | -0.82% | 11.15 | 4.25 | 77.72% | 112.02% |
MGNX | 288.6M | 152.5M | -11.24% | 54.82% | 38.75 | 1.89 | 127.84% | 103.41% |
CRBP | 30.1M | - | 1.72% | 3677.78% | -0.65 | - | - | -31.51% |
Corbus Pharmaceuticals Holdings News
Returns for CRBP
Cumulative Returns on CRBP
1.2%
7-Year Cumulative Returns
-0.4%
5-Year Cumulative Returns
60.7%
3-Year Cumulative Returns
Risks for CRBP
What is the probability of a big loss on CRBP?
100%
Probability that Corbus Pharmaceuticals Holdings stock will be more than 20% underwater in next one year
100%
Probability that Corbus Pharmaceuticals Holdings stock will be more than 30% underwater in next one year.
89.2%
Probability that Corbus Pharmaceuticals Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CRBP drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Corbus Pharmaceuticals Holdings was unfortunately bought at previous high price.
Drawdowns
Financials for Corbus Pharmaceuticals Holdings
Income Statement (Last 12 Months)(In Thousands)
| Income Statement (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 |
| Revenue | -42.7% | 882 | 1,540 | 2,673 | 2,823 | 3,937 | 5,853 | 7,212 | 36,020 | 36,144 | 35,497 | 33,998 | 5,758 | 4,822 | 2,895 | 2,600 | 2,097 | 2,440 | 2,816 | 2,762 | 2,809 | 1,911 |
| Operating Expenses | -16.8% | 56,871 | 68,343 | 89,575 | 111,162 | 126,747 | 135,041 | 127,523 | 116,487 | 113,248 | 103,003 | 91,305 | 77,163 | 61,570 | 52,914 | 44,678 | 39,072 | 35,003 | 32,089 | - | - | - |
| S&GA Expenses | -23.8% | 16,417 | 21,551 | 23,955 | 26,122 | 28,480 | 29,396 | 27,249 | 24,718 | 23,643 | 21,105 | 18,751 | 16,531 | 12,956 | 11,794 | 10,743 | 9,634 | 8,964 | 8,957 | - | - | - |
| R&D Expenses | -33.6% | 31,062 | 46,792 | 65,619 | 85,040 | 98,267 | 105,645 | 100,274 | 91,769 | 89,605 | 81,898 | 72,554 | 60,632 | 48,614 | 41,120 | 33,934 | 29,438 | 26,039 | 23,132 | - | - | - |
| Interest Expenses | 13.6% | -1,830 | -2,119 | -2,181 | -1,767 | -1,028 | -188 | 559 | 551 | 1,228 | 302 | 14.00 | 11.00 | 10.00 | 10.00 | 13.00 | 13.00 | 12.00 | 12.00 | - | - | - |
| Net Income | -3.7% | -45,640 | -43,991 | -76,710 | -97,677 | -111,269 | -129,238 | -115,133 | -74,875 | -71,453 | -62,179 | -55,989 | -70,211 | -55,672 | -49,059 | -41,424 | -36,651 | -32,421 | -29,298 | - | - | - |
| Net Income Margin | -81.2% | -51.76* | -28.57* | -28.70* | -29.55* | -28.26* | -8.83* | -4.55* | -2.08* | -1.98* | -1.75* | - | - | - | - | - | - | - | - | - | - | - |
| Free Cashflow | 14.9% | -48,237 | -56,653 | -84,820 | -93,914 | -100,170 | -105,851 | -96,822 | -86,772 | -48,463 | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -15.3% | 44.00 | 52.00 | 66.00 | 74.00 | 82.00 | 96.00 | 108 | 120 | 121 | 140 | 102 | 96.00 | 98.00 | 65.00 | 49.00 | 68.00 | 84.00 | 101 | 47.00 | 61.00 | 70.00 |
| Current Assets | -16.6% | 38.00 | 46.00 | 60.00 | 67.00 | 75.00 | 88.00 | 100 | 112 | 112 | 130 | 92.00 | 85.00 | 88.00 | 55.00 | 38.00 | 58.00 | 75.00 | 93.00 | 44.00 | 58.00 | 68.00 |
| Cash Equivalents | 14.0% | 8.00 | 7.00 | 17.00 | 12.00 | 26.00 | 57.00 | 25.00 | 37.00 | 36.00 | 67.00 | 85.00 | 82.00 | 63.00 | 47.00 | 32.00 | 55.00 | 73.00 | 90.00 | 42.00 | 56.00 | 65.00 |
| Net PPE | -11.1% | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Liabilities | -2.8% | 34.00 | 35.00 | 33.00 | 32.00 | 33.00 | 35.00 | 39.00 | 42.00 | 44.00 | 49.00 | 57.00 | 67.00 | 50.00 | 43.00 | 43.00 | 38.00 | 37.00 | 59.00 | 19.00 | 18.00 | 15.00 |
| Current Liabilities | 14.1% | 16.00 | 14.00 | 13.00 | 17.00 | 16.00 | 15.00 | 17.00 | 17.00 | 19.00 | 24.00 | 32.00 | 41.00 | 42.00 | 35.00 | 35.00 | 31.00 | 29.00 | 52.00 | 18.00 | 17.00 | 13.00 |
| LT Debt, Non Current | -19.0% | 11.00 | 14.00 | 16.00 | 9.00 | 12.00 | 14.00 | 16.00 | 19.00 | 18.00 | 18.00 | 18.00 | 18.00 | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | -42.2% | 10.00 | 16.00 | 33.00 | 42.00 | 49.00 | 61.00 | 69.00 | 78.00 | 77.00 | 92.00 | 45.00 | 29.00 | 48.00 | 23.00 | 6.00 | 30.00 | 47.00 | 42.00 | 28.00 | 43.00 | 55.00 |
| Retained Earnings | -2.1% | -418 | -409 | -392 | -381 | -372 | -359 | -349 | -339 | -337 | -320 | -304 | -295 | -260 | -222 | -192 | -166 | -145 | -147 | -121 | -104 | -89.46 |
| Additional Paid-In Capital | 0.4% | 428 | 426 | 425 | 423 | 422 | 420 | 419 | 417 | 414 | 412 | 349 | 325 | 309 | 245 | 199 | 196 | 193 | 190 | 149 | 147 | 145 |
| Shares Outstanding | 4.9% | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 10.5% | -37,615 | -42,044 | -37,544 | -39,792 | -31,690 | -36,989 | -48,183 | -56,705 | -84,815 | -93,894 | -99,685 | -104,023 | -93,856 | -83,640 | -45,720 | -37,223 | -28,983 | -18,149 | -30,067 | -25,116 | -22,601 |
| Share Based Compensation | -13.4% | 4,465 | 5,154 | 5,720 | 6,244 | 7,498 | 8,492 | 9,480 | 10,028 | 11,060 | 11,901 | 12,458 | 13,214 | 12,561 | 12,030 | 11,982 | 10,834 | 9,815 | 8,814 | 7,610 | 7,121 | 6,513 |
| Cashflow From Investing | 374.8% | 20,166 | -7,338 | 30,074 | 15,117 | 21,372 | 26,970 | -73,416 | -70,187 | -70,527 | -57,445 | -484 | -1,828 | -2,965 | -3,132 | -2,742 | -1,700 | -612 | -1,104 | -2,300 | -2,630 | -2,570 |
| Cashflow From Financing | 108.9% | 28.00 | -319 | -533 | 1* | 8.00 | 83.00 | 60,823 | 81,790 | 128,625 | 172,355 | 154,875 | 133,892 | 87,136 | 43,471 | 38,463 | 38,114 | 38,074 | 38,218 | 11,420 | 46,610 | 46,616 |
CRBP Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Operating expenses: | ||||
| Research and development | $ 4,248,705 | $ 2,499,642 | $ 17,637,048 | $ 5,785,878 |
| General and administrative | 3,940,286 | 4,840,368 | 7,848,968 | 10,071,291 |
| Litigation settlement | 0 | 5,000,000 | 0 | 5,000,000 |
| Total operating expenses | 8,188,991 | 12,340,010 | 25,486,016 | 20,857,169 |
| Operating loss | (8,188,991) | (12,340,010) | (25,486,016) | (20,857,169) |
| Other income (expense), net: | ||||
| Other income (expense), net | 182,657 | (208,683) | 412,164 | (402,034) |
| Interest income (expense), net | (775,586) | (490,339) | (1,453,608) | (949,248) |
| Foreign currency exchange gain (loss), net | (1,921) | (209,856) | (1,193) | (477,679) |
| Other expense, net | 594,850 | (908,878) | (1,042,637) | (1,828,961) |
| Net loss | $ (8,783,841) | $ (13,248,888) | $ (26,528,653) | $ (22,686,130) |
| Earnings Per Share, Basic | $ (2.05) | $ (3.18) | $ (6.27) | $ (5.44) |
| Earnings Per Share, Diluted | $ 2.05 | $ (3.18) | $ (6.27) | $ (5.44) |
| Weighted Average Number of Shares Outstanding, Basic | 4,277,701 | 4,170,464 | 4,229,894 | 4,170,255 |
| Weighted Average Number of Shares Outstanding, Diluted | 4,277,701 | 4,170,464 | 4,229,894 | 4,170,255 |
| Comprehensive loss: | ||||
| Net loss | $ (8,783,841) | $ (13,248,888) | $ (26,528,653) | $ (22,686,130) |
| Other comprehensive income (loss): | ||||
| Change in unrealized gain (loss) on marketable debt securities | 44,681 | 50,373 | 102,304 | (56,875) |
| Total other comprehensive income (loss) | 44,681 | 50,373 | 102,304 | (56,875) |
| Total comprehensive loss | $ (8,739,160) | $ (13,198,515) | $ (26,426,349) | $ (22,743,005) |
CRBP Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 8,349,346 | $ 17,002,715 |
| Investments | 28,216,560 | 42,194,296 |
| Restricted cash | 192,475 | 192,475 |
| Prepaid expenses and other current assets | 1,515,616 | 791,616 |
| Total current assets | 38,273,997 | 60,181,102 |
| Restricted cash | 477,425 | 477,425 |
| Property and equipment, net | 1,273,602 | 1,613,815 |
| Operating lease right of use assets | 3,486,416 | 3,884,252 |
| Other assets | 211,943 | 155,346 |
| Total assets | 43,723,383 | 66,311,940 |
| Current liabilities: | ||
| Notes payable | 51,157 | 353,323 |
| Accounts payable | 1,505,734 | 2,173,963 |
| Accrued expenses | 6,418,803 | 5,999,252 |
| Derivative liability | 36,868 | 36,868 |
| Operating lease liabilities, current | 1,357,240 | 1,280,863 |
| Current portion of long-term debt | 7,016,096 | 2,795,669 |
| Total current liabilities | 16,385,898 | 12,639,938 |
| Long-term debt, net of debt discount | 11,319,365 | 15,984,426 |
| License agreement payable, noncurrent | 2,500,000 | 0 |
| Other long-term liabilities | 22,205 | 22,205 |
| Operating lease liabilities, noncurrent | 3,975,329 | 4,675,354 |
| Total liabilities | 34,202,797 | 33,321,923 |
| Stockholders' equity | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no sharesissued and outstanding at June 30, 2023 and December 31, 2022. See Note 11 | 0 | 0 |
| Common stock, $0.0001 par value; 300,000,000 shares authorized,4,422,741 and 4,171,297 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 442 | 417 |
| Additional paid-in capital | 428,153,252 | 425,196,359 |
| Accumulated deficit | (418,609,320) | (392,080,667) |
| Accumulated other comprehensive loss | (23,788) | (126,092) |
| Total stockholders’ equity | 9,520,586 | 32,990,017 |
| Total liabilities and stockholders’ equity | $ 43,723,383 | $ 66,311,940 |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.